A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination with Capecitabine Tablets in Patients with HER2-Positive Advanced Solid Tumors
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Suzhou Zanrong Pharma Limited
Start Date
July 17, 2020
End Date
June 9, 2025
Administered By
Duke Cancer Institute
Awarded By
Suzhou Zanrong Pharma Limited
Start Date
July 17, 2020
End Date
June 9, 2025